Study design
This randomized clinical trial was performed at a tertiary university hospital in China. The study was approved by the Ethics committee of Peking University First Hospital (Reference Number: 2020–247, on 30/10/2020) and registered prior to patient enrollment at Chinese Clinical Trial Registry (ChiCTR2000040343, on 28/11/2020). Written informed consent was obtained from all patients before enrollment. The principles of Declaration of Helsinki were followed for this study. This manuscript adheres to the applicable CONSORT guidelines.